Fungemia in a University Hospital 1984–1988

References

• Karabinis A, Hill C, Leclercq B, Tancrede C, Baume D, Andremont A. Risk factors for candidemia in cancer patients: a case‐control study. J Clin Microbiol 1988; 26: 429–432
   PubMed Web of Science ®Google Scholar
• Horn R, Wong B, Kiehn T E, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985; 7: 646–655
   PubMedGoogle Scholar
• Eilard T. Isolation of fungi in blood cultures. A review of fungal infections in the western part of Sweden 1970–1982. Scand J Infect Dis 1987; 19: 145–156
   PubMed Web of Science ®Google Scholar
• Burchard K W, Minor L B, Slotman G J, Gann D S. Fungal sepsis in surgical patients. Arch Surg 1983; 118: 217–221
   PubMedGoogle Scholar
• Weese‐Mayer D E, Fondriest D W, Brouillette R T, Shulman S T. Risk factors associated with candidemia in the neonatal intensive care unit: a case‐control study. Pediatr Infect Dis 1987; 6: 190–196
   Google Scholar
• Degregorio M W, Lee W MF, Linker C A, Jacobs R A, Ries C A. Fungal infections in patients with acute leukemia. Am J Med 1982; 73: 543–548
   PubMed Web of Science ®Google Scholar
• Maksymiuk A W, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey G P. Systemic candidiasis in cancer patients. Am J Med 1984; 77: 20–27
   PubMed Web of Science ®Google Scholar
• Rantala A, Niinikoski J, Lehtonen O ‐P. Yeasts in blood cultures: Impact of early therapy. Scand J Infect Dis 1989; 21: 557–561
   PubMed Web of Science ®Google Scholar
• Barnett J A, Payne R W, Yarrow D. Yeasts: characteristics and identification. Cambridge University Press, Cambridge 1986
   Google Scholar
• Nielsen H, Stenderup J, Bruun B. Fungemia with Saccharomycetaceae. Report of four cases and review of the literature. Scand J Infect Dis 1990; 22: 581–584
   PubMed Web of Science ®Google Scholar
• Telenti A, Roberts G D. Fungal blood cultures. Eur J Clin Microbiol Infect Dis 1989; 8: 825–831
   PubMed Web of Science ®Google Scholar
• Kiehn T E. Bacteremia and fungemia in the immunocompromised patient. Eur J Clin Microbiol Infect Dis 1989; 8: 832–837
   PubMed Web of Science ®Google Scholar
• Stahel R A, Vogt P, Schuler G, Ruttner J R, Frick P, Oelz O. Systemic fungal infections in haematological malignancies: a growing problem. J Infect 1982; 5: 269–275
   Web of Science ®Google Scholar
• Haron E, Feld R, Tuffnell P, Patterson B, Hasselback R, Matlow A. Hepatic candidiasis: an increasing problem in immunocompromised patients. Am J Med 1987; 83: 17–26
   PubMed Web of Science ®Google Scholar
• Koch C, Høiby N. Severe child abuse presenting as polymicrobial bacteremia. Acta Pædiatr Scand 1988; 77: 940–943
   PubMed Web of Science ®Google Scholar
• Thaler M, Pastakia B, Shawker T H, O'Leary T, Pizzo P A. Hepatic candidiasis in cancer patients: The evolving picture of the syndrome. Ann Intern Med 1988; 108: 88–100
   PubMed Web of Science ®Google Scholar
• Young R C, Bennett J E, Geelhoed G W, Levine A S. Fungemia with compromised host resistance: a study of 70 cases. Ann Intern Med 1974; 80: 605–612
   PubMed Web of Science ®Google Scholar
• Pfaller M, Cabezudo I, Koontz F, Bale M, Gingrich R. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur J Clin Microbiol 1987; 6: 628–633
   PubMedGoogle Scholar
• Fainstein V, Rodriguez V, Turck M, Hermann G, Rosenbaum B, Bodey G P. Patterns of oropharyngeal and fecal flora in patients with acute leukemia. J Infect Dis 1981; 144: 10–18
   PubMed Web of Science ®Google Scholar
• Stamm A M, Diasio R B, Dismukes W E, Shadomy S, Cloud G A, Bowles C A, Karam G H, Espinel‐Ingroff A. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987; 83: 236–242
   PubMed Web of Science ®Google Scholar
• Speller D CE, Cartwright R Y, Evans E GV, Hay R J, Mackenzie D WR, Milne L JR, Odds F C, Warnock D W, Wingfield H J. Laboratory methods for flucytosine (5‐fluorocytosine). J Antimicrob Chemother 1984; 14: 1–8
   Web of Science ®Google Scholar
• Calhoun D L, Roberts G D, Galgiani J N, Bennett J E, Feingold D S, Jorgensen J, Kobayashi G S, Shadomy S. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol 1986; 23: 298–301
   PubMed Web of Science ®Google Scholar
• Hamilton‐Miller J MT. A comparative in vitro study of amphotericin B, clotrimazole and 5‐fluorocytosine against clinically isolated yeasts. Sabouraudia 1972; 10: 276–283
   PubMedGoogle Scholar
• Normark S, Schönebeck J. In vitro studies of 5‐fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrob Agents Chemother 1972; 2: 114–121
   PubMed Web of Science ®Google Scholar
• Schönebeck J, Ånséhn S. 5‐fluorocytosine resistance in Candida spp. and Torulopsis glabrata. Sabouraudia 1973; 11: 10–20
   PubMedGoogle Scholar
• Shadomy S, Kirchoff C B, Ingroff A E. In vitro activity of 5‐fluorocytosine against Candida and Torulopsis species. Antimicrob Agents Chemother 1973; 3: 9–14
   PubMed Web of Science ®Google Scholar
• Hoeprich P D, Huston A C. Susceptibility of Coccidioides immitis, Candida albicans, and Cryptococcus neoformans to amphotericin B, flucytosine, and cotrimazole. J Infect Dis 1975; 132: 133–141
   PubMed Web of Science ®Google Scholar
• Pappagianis D, Collins M S, Hector R, Remington J. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother 1979; 16: 123–126
   PubMed Web of Science ®Google Scholar
• Stiller R L, Bennett J E, Scholer H J, Wall M, Polak A, Stevens D A. Susceptibility to 5‐fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother 1982; 22: 482–487
   PubMed Web of Science ®Google Scholar
• Defever K S, Whelan W L, Rogers A L, Beneke E S, Veselenak J M, Soll D R. Candida albicans resistance to 5‐fluorocytosine: frequency of partially resistant strains among clinical isolates. Antimicrob Agents Chemother 1982; 22: 810–815
   PubMed Web of Science ®Google Scholar
• Dick J D, Merz W G, Saral R. Incidence of polyene‐resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980; 18: 158–163
   PubMed Web of Science ®Google Scholar
• Auger P, Dumas C, Joly J. A study of 666 strains of Candida albicans. Correlation between serotype and susceptibility to 5‐fluorocytosine. J Infect Dis 1979; 139: 590–594
   PubMed Web of Science ®Google Scholar
• Montgomerie J Z, Edwards J E, Guze L B. Synergism of amphotericin B and 5‐fluorocytosine for Candida species. J Infect Dis 1975; 132: 82–86
   PubMed Web of Science ®Google Scholar
• Titsworth E, Grunberg E. Chemotherapeutic activity of 5‐fluorocytosine and amphotericin B against Candida albicans in mice. Antimicrob Agents Chemother 1973; 4: 306–308
   PubMed Web of Science ®Google Scholar
• Rabinovich S, Shaw B D, Bryant T, Donta S T. Effect of 5‐fluorocytosine and amphotericin B on Candida aibicans infection in mice. J Infect Dis 1974; 130: 28–31
   PubMed Web of Science ®Google Scholar
• Eilard T, Beskov D, Norrby R, Wåhlén P, Alestig K. Combined treatment with amphotericin B and flucytosine in severe fungal infections. J Antimicrob Chemother 1976; 2: 239–246
   PubMedGoogle Scholar
• Bennett J E, Dismukes W E, Duma R J, Medoff G, Sande M A, Gallis H, Leonard J, Fields B T, Bradshaw M, Haywood H, McGee Z A, Cate T R, Cobbs C G, Warner J F, Alling D W. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301: 126–131
   PubMed Web of Science ®Google Scholar